Table 1.
Donors for IFN-γ ELISpot assays and flow cytometric analysis | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
SARS-CoV-2-infected |
Uninfected |
Uninfected, COVID-19-vaccinated |
|||||||||
No. | Sex | Age (years) | Days from 1st COVID+ test to blood draw | Days from 1st symptoms to blood draw | No. | Sex | Age (years) | No. | Sex | Age (years) | Days from 2nd COVID-19 vaccine dose to blood draw |
1 | M | 74 | 22 | 11 | 1 | F | 32 | 1 | F | 32 | 74 |
2 | F | 89 | 4 | 5 | 2 | F | 27 | 2 | M | 67 | 80 |
3 | M | 52 | 37 | 36 | 3 | M | 38 | 3 | F | 35 | 71 |
4 | F | 61 | 5 | 5 | 4 | F | 35 | ||||
5 | F | 25 | 94 | 98 | 5 | F | 58 | ||||
6 | F | 25 | 6 | 11 | 6 | M | 26 | ||||
7 | M | 36 | 69 | n.k. | 7 | M | 67 | ||||
8 | F | 47 | 100 | 109 | 8 | M | 56 | ||||
9 | F | 68 | 2 | 5 | |||||||
10 | M | 72 | 5 | 9 | |||||||
11 | F | 52 | 124 | 133 | |||||||
12 | F | 37 | 94 | 96 | |||||||
13 | F | 51 | 120 | 120 | |||||||
14 | F | 64 | 131 | 139 | |||||||
15 | M | 32 | 204 | n.k. | |||||||
16 | M | 54 | 13 | 13 | |||||||
17 | M | 52 | 96 | n.k. | |||||||
18 |
F |
50 |
112 |
n.k. |
|||||||
Donors for V(D)J clonotyping and scRNA-seq studies | |||||||||||
SARS-CoV-2-infected | Uninfected | ||||||||||
No. | Sex | Age (years) | Days from first COVID+test to blood draw | Days from first symptoms to blood draw | No. | Sex | Age (years) | ||||
1 | F | 25 | 192 | 196 | 1 | F | 32 | ||||
2 | M | 52 | 156 | 155 | 2 | M | 67 | ||||
3 | M | 32 | 204 | n.k. | 3 | F | 35 |
Demographics of COVID-19-convalescent patients (SARS-CoV-2-infected as assessed by positive COVID-19 test), uninfected participants, and uninfected COVID-19-mRNA-vaccinated participants for IFN-γ ELISpot assays and flow cytometry studies, and SARS-CoV-2-infected and uninfected donors for V(D)J clonotyping and scRNA-seq studies. F, female; M, male; N/A, not applicable; n.k., not known.